Yahoo Finance • 29 days ago
Bausch + Lomb recently announced positive results from a study on XIIDRA, enhancing its position in treating dry eye disease in contact lens wearers. This news, alongside the U.S. launch of ASANA gas permeable lenses and improved Q2 earnin... Full story
Yahoo Finance • 2 months ago
What Happened? Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 3.1% in the afternoon session after comments from Federal Reserve Chair Jerome Powell raised investor hopes for future interest rate cuts. The move came as U.S. sto... Full story
Yahoo Finance • 2 months ago
(Reuters) -Contact lens maker Bausch + Lomb said on Monday Brett Icahn and Gary Hu have resigned from its board of directors after the termination of the agreement with billionaire investor Carl Icahn and some of his affiliates. The agree... Full story
Yahoo Finance • 2 months ago
[Bausch Health US headquarters in Bridgewater, NJ, USA.] JHVEPhoto/iStock Editorial via Getty Images Bausch Health (NYSE:BHC [https://seekingalpha.com/symbol/BHC]) shares added ~4% on Friday after John Paulson, a board member of the Canad... Full story
Yahoo Finance • 2 months ago
Insightful Moves in the Second Quarter of 2025 Howard Marks (Trades, Portfolio) recently submitted the 13F filing for the second quarter of 2025, providing insights into his investment moves during this period. As the Chairman of Oaktree... Full story
Yahoo Finance • 2 months ago
Bausch + Lomb Corporation (NYSE:BLCO, TSX:BLCO), a prominent player in the healthcare sector specializing in ophthalmology, has been navigating a complex landscape of market opportunities and corporate challenges. With a market capitalizat... Full story
Yahoo Finance • 2 months ago
What Happened? A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report,... Full story
Yahoo Finance • 2 months ago
Key Points Revenue (GAAP) rose 5% year over year to $1.28 billion, surpassing expectations by $18 million. Adjusted EPS (non-GAAP) came in at $0.07, above the $0.06 consensus but down sharply from last year's $0.13. Net loss narrowed to $... Full story
Yahoo Finance • 2 months ago
Earnings Call Insights: Bausch + Lomb (BLCO) Q2 2025 MANAGEMENT VIEW * CEO Brenton L. Saunders reported "our constant currency revenue growth speaks to the breadth and depth of our portfolio and is driven by a mix of hero products and... Full story
Yahoo Finance • 2 months ago
Trader at NYSE by Orhan Akkurt via Shutterstock September S&P 500 E-Mini futures (ESU25) are up +0.04%, andSeptember Nasdaq 100 E-Mini futures (NQU25) are up +0.10% this morning, pointing to a cautious open on Wall Street as investors awa... Full story
Yahoo Finance • 2 months ago
(RTTNews) - Bausch + Lomb Corporation (BLCO) Tuesday said results from a Phase 3 study showed that LUMIFY Preservative Free is non inferior to LUMIFY redness reliever eye drops for reducing redness in the eyes. In the study, participants... Full story
Yahoo Finance • 3 months ago
Bausch & Lomb Corp. (NYSE:BLCO, TSX:BLCO) announced changes to the employment agreement of Chief Executive Officer Brenton L. Saunders, according to a press release statement based on a filing with the Securities and Exchange Commission.... Full story
Yahoo Finance • 3 months ago
MarketNewsUpdatesNews Commentary NEW YORK, July 22, 2025 /CNW/ -- According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030... Full story
Yahoo Finance • 3 months ago
Company Logo North America leads with over 34% market share, while APAC shows a robust growth of 9.03%. Major players like Alcon, Carl Zeiss, and Johnson & Johnson drive innovation in advanced ocular devices and eye health solutions. Oph... Full story
Yahoo Finance • 3 months ago
VAUGHAN, Ontario, June 30, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on W... Full story
Yahoo Finance • 3 months ago
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Bausch + Lomb Corporation (“Bausch & Lomb” or the “Company”) (NYSE:BL... Full story
Yahoo Finance • 4 months ago
Barclays lowered its price target on Bausch & Lomb (NYSE: BLCO) from $19 to $16 on June 6, maintaining an Equalweight rating. The revision reflects a more cautious outlook on the company’s near-term financial performance. The firm trimmed... Full story
Yahoo Finance • 4 months ago
* Bausch + Lomb (TSX:BLCO:CA [https://seekingalpha.com/symbol/BLCO:CA]) on Wednesday said its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb, have priced the offering of €675M aggregate principal amount of senior secured fl... Full story
Yahoo Finance • 4 months ago
AMSTERDAM/NEW YORK - Bausch + Lomb Netherlands B.V. and Bausch & Lomb Incorporated announced Wednesday they are offering €600 million in senior secured notes with a 5.5-year floating rate, according to a stabilization notice. J.P. Morgan... Full story
Yahoo Finance • 4 months ago
Bausch + Lomb Corp. (NYSE:BLCO, TSX:BLCO), a prominent player in the healthcare sector specializing in eye health products, has been navigating a complex market landscape. According to InvestingPro data, the company has demonstrated strong... Full story